Clinical Associate Professor, Internal Medicine, University of Maryland School of Medicine

Nephrology

Doctor John H. Sadler, MD is an expert in the field of Nephrology. He graduated from Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine Doctor John H. Sadler, MD is also published. He has 68 publications published. The lastest publication: "New dialysis-specific COOP charts may improve ESRD patient assessment.'

Publications

---

• Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring fo...
• The 2009 proposed rule for prospective ESRD payment: perspectives from a not-for-profit small dialysis organization.
• Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD.
• With the pursuit of quality comes a retreat from personal care: the path of medical practice and dialysis care in America.
• Hemoglobin levels, quality of life, and survival.
• We are overreacting to our hemoglobin fear.
• Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease.
• What are the barriers to ideal patient care?
• How strong are patients' preferences in choices between dialysis modalities and doses?
• Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis.
• CMS' pay-per-visit idea for nephrologists is a reasonable one--let's see if it improves patient outcomes.
• Frequency of patient-physician contact and patient outcomes in hemodialysis care.
• The Medicare ESRD program and the U.S. renal community: an all too consistent history.
• Microbiological quality requirements for dialysate: is it time for a change?
• Cost-quality trade-offs in dialysis care: a national survey of dialysis facility administrators.
• Basilic vein to brachial artery fistula: a new access for chronic hemodialysis.
• The therapeutic efficacy of hemodialysis in schizophrenia.
• Influence of circulating insulin-like growth factor-I compared with that of intrarenal insulin-like growth factor-I on proximal nephron receptor density in rats.
• Bretylium kinetics in renal insufficiency.
• The use of basilic vein and brachial artery as an A-V fistula for long term hemodialysis.
• Why choose nephrology?
• A review of worldwide use of patient questionnaires in dialysis.
• The FDA guidelines for water treatment equipment: its impact on the renal community.
• Should the nephrologist practice primary care? Yes.
• Highway to computerization can be bumpy, but worth the trip for the renal team.
• The RPA. Celebrating 25 years as an advocate for nephrology.
• Sadler sees hope in new rehabilitation efforts.
• Quality assurance: principles and practice.
• ESRD disillusionment revisited.
• The political economy of nephrology.
• Evaluation of the effects of cyclosporine and HLA-typed source leukocyte transfusions (apheresis by-products) on the immune systems of highly sensitized prospective re...
• The prognostic value of the eosinophil in acute renal allograft rejection.
• Effects of allostimulation and cyclosporine therapy on cytotoxic antibody production in highly sensitized prospective renal transplant recipients.
• Enzyme-linked immunosorbent assay for serum renal tubular antigen in kidney transplant patients.
• Reevaluation of T cell subset monitoring in cyclosporine-treated renal allograft recipients.
• Centers for Disease Control and Prevention: a clinician's view of the past, present, and future.
• Core indicator study: evaluating the results.
• Quality of Life Award--a difficult choice.
• Race and access to erythropoietin by patients on hemodialysis.
• Roots & uprisings of the RPA.
• The nursing shortage: a long view.
• Haemodialysis patients'' readiness to pursue live donor kidney transplantation.
• Renal rehabilitation: obstacles, progress, and prospects for the future.
• Measuring and improving the health status of end stage renal disease patients.
• Short-term impact of an educational program promoting live donor kidney transplantation in dialysis centers.
• Health promotion for end-stage renal disease patients.
• Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
• Quantity and quality of ESRD treatment in the United States of America.
• "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc.
• Use of focus groups to identify concerns about dialysis. Choice Study.
• Patients' rights and responsibilities: a physician's view.
• Trying to measure quality? Ask the patient.
• Standards revised for water treatment, concentrate labeling.
• Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality.
• Using our broader base of knowledge to improve outcomes for ESRD patients.
• New dialysis-specific COOP charts may improve ESRD patient assessment.
• The best outcomes: are they in for-profit or not-for-profit units?
• Measuring, managing, and improving quality in the end-stage renal disease treatment setting: committee statement.
• Assessing health and quality of life outcomes in dialysis: a report on an Institute of Medicine workshop.
• US nephrologists' recommendation of dialysis modality: results of a national survey.
• U.S. nephrologists'' attitudes towards renal transplantation: results from a national survey.
• Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.
• The timing of specialist evaluation in chronic kidney disease and mortality.
• Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire.
• Frequency of patient-physician contact in chronic kidney disease care and achievement of clinical performance targets.
• Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study.
• MYH9 is associated with nondiabetic end-stage renal disease in African Americans.

Schools

---

• Duke University School Of Medicine

• Grady Mem Hospital

• Vet Affairs Med Center

Doctors Specialties

---

• Nephrology

Accepted Insurances

---

Education

---

• Duke University School of Medicine

Hospital

---

• University of Maryland Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Darius M. Cameron, MD This Doctor is OpenDoctor Recommended.
	Dr. Mabel A. Bodell, MD
	Dr. Sanjeev R. Shah, MD
	Dr. Eugene A. Magee, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael C. Yen, MD
	Dr. Manju A. Mavanur, MD This Doctor is OpenDoctor Recommended.
	Dr. Tariq J. Shafi, MD This Doctor is OpenDoctor Recommended.
	Dr. Emilio Ramos, MD This Doctor is OpenDoctor Recommended.
	Dr. Preeti Chandra, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard Ugarte, MD This Doctor is OpenDoctor Recommended.
	Dr. Heather J. Agee, MD This Doctor is OpenDoctor Recommended.
	Dr. Michelle M. Estrella, MD This Doctor is OpenDoctor Recommended.
	Dr. Jean C. Bassila, MD This Doctor is OpenDoctor Recommended.
	Dr. Melanie Haroun, MD This Doctor is OpenDoctor Recommended.
	Dr. Alison Grazioli, MD
	Dr. Sumeska Thavarajah, MD This Doctor is OpenDoctor Recommended.
	Dr. Lori-Ann Fisher, MD
	Dr. Gaurav Gupta, MD
	Dr. Karl L. Womer, MD This Doctor is OpenDoctor Recommended.
	Dr. Raymond D. Pratt, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog